Jane Street Group LLC decreased its position in Aadi Bioscience, Inc. (NASDAQ:AADI - Free Report) by 80.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 25,989 shares of the company's stock after selling 108,245 shares during the period. Jane Street Group LLC owned about 0.11% of Aadi Bioscience worth $54,000 at the end of the most recent reporting period.
Separately, BML Capital Management LLC acquired a new stake in Aadi Bioscience in the 3rd quarter valued at about $4,120,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.
Aadi Bioscience Price Performance
AADI traded down $0.11 during midday trading on Thursday, reaching $3.13. 182,073 shares of the company's stock were exchanged, compared to its average volume of 360,257. Aadi Bioscience, Inc. has a 1-year low of $1.21 and a 1-year high of $3.81. The stock has a market capitalization of $77.15 million, a PE ratio of -1.37 and a beta of 0.65. The business's 50-day moving average price is $2.67 and its 200 day moving average price is $2.06.
Aadi Bioscience (NASDAQ:AADI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. During the same period in the previous year, the firm posted ($0.60) EPS. As a group, analysts expect that Aadi Bioscience, Inc. will post -2.04 EPS for the current fiscal year.
About Aadi Bioscience
(
Free Report)
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Featured Stories
Before you consider Aadi Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.
While Aadi Bioscience currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
